SUMMARY: The Alzheimer’s Drug Discovery Foundation (ADDF) and the Robert A. and Renée E. Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. Although only ~20% of humans are APOE ε4 carriers, these individuals account for up to 65% of all Alzheimer’s disease cases. Therapies that target apoE are critically needed now. Recent scientific advances have made this a possibility.
This program will allow the ADDF to substantially build on its strategic investment in apoE drug
discovery and development and will support both preclinical and clinical stage programs.
MECHANISM(S) OF SUPPORT: Applications may be submitted by non-profit academic institutions and for-profit biotechnology companies, both public and private, worldwide. Please note that funding to biotechnology companies is typically made as a program related investment. The ADDF will provide 1 or 2 years funding for up to $300,000 per application for pre-clinical programs, and up to $1,000,000 per application for clinical trials of novel agents such as phase 1b or 2a studies employing biomarkers as outcome measures. All applications must be submitted electronically at www.alzdiscovery.org.
2013 QUARTERLY DEADLINES*
*Letter of Intent is due two weeks prior to deadline